Tatva Chintan Pharma Chem Limited (NSE:TATVA)
India · Delayed Price · Currency is INR 1,133.20
-13.60 (-1.19%)
May 29, 2026, 3:30 PM IST
Tatva Chintan Pharma Chem Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 5,059 | 3,827 | 3,935 | 4,236 | 4,336 | |
Revenue Growth (YoY) | 32.18% | -2.74% | -7.11% | -2.31% | 44.38% |
Cost of Revenue | 2,245 | 2,060 | 1,830 | 2,327 | 2,015 |
Gross Profit | 2,813 | 1,767 | 2,105 | 1,910 | 2,321 |
Selling, General & Admin | 629.32 | 545.27 | 563.05 | 430.87 | 319.58 |
Other Operating Expenses | 1,252 | 878.78 | 848.1 | 798.39 | 915.23 |
Operating Expenses | 2,250 | 1,701 | 1,667 | 1,325 | 1,317 |
Operating Income | 563.11 | 66.82 | 437.83 | 584.69 | 1,005 |
Interest Expense | -28.51 | -8.96 | -61.51 | -79.97 | -43.51 |
Interest & Investment Income | - | 4.87 | 23.64 | 38.38 | 45.4 |
Currency Exchange Gain (Loss) | - | 12.45 | 28.15 | -72.9 | 38.41 |
Other Non Operating Income (Expenses) | 35.49 | 0.04 | 5.86 | 10.89 | -4.15 |
EBT Excluding Unusual Items | 570.09 | 75.22 | 433.97 | 481.09 | 1,041 |
Gain (Loss) on Sale of Investments | - | 0.75 | 1.89 | - | - |
Gain (Loss) on Sale of Assets | - | -1.18 | -1.48 | -0.01 | -0.51 |
Other Unusual Items | - | 1 | 1.62 | -35.43 | 0.73 |
Pretax Income | 570.09 | 75.79 | 436 | 445.65 | 1,041 |
Income Tax Expense | 149.55 | 18.66 | 132.46 | -9.22 | 82.47 |
Net Income | 420.54 | 57.13 | 303.54 | 454.87 | 958.74 |
Net Income to Common | 420.54 | 57.13 | 303.54 | 454.87 | 958.74 |
Net Income Growth | 636.11% | -81.18% | -33.27% | -52.55% | 83.45% |
Shares Outstanding (Basic) | 23 | 23 | 23 | 22 | 21 |
Shares Outstanding (Diluted) | 23 | 23 | 23 | 22 | 21 |
Shares Change (YoY) | -0.01% | 2.20% | 3.27% | 3.10% | 7.03% |
EPS (Basic) | 17.98 | 2.44 | 13.26 | 20.52 | 44.59 |
EPS (Diluted) | 17.98 | 2.44 | 13.26 | 20.52 | 44.59 |
EPS Growth | 636.89% | -81.60% | -35.38% | -53.98% | 71.39% |
Free Cash Flow | -822.85 | -516.01 | -304.71 | -1,753 | -689.27 |
Free Cash Flow Per Share | -35.18 | -22.06 | -13.31 | -79.10 | -32.06 |
Dividend Per Share | 2.000 | 1.000 | 2.000 | 2.000 | 2.000 |
Dividend Growth | 100.00% | -50.00% | - | - | -60.00% |
Gross Margin | 55.61% | 46.18% | 53.50% | 45.08% | 53.53% |
Operating Margin | 11.13% | 1.75% | 11.13% | 13.80% | 23.17% |
Profit Margin | 8.31% | 1.49% | 7.71% | 10.74% | 22.11% |
Free Cash Flow Margin | -16.27% | -13.48% | -7.74% | -41.39% | -15.90% |
EBITDA | 931.58 | 332.06 | 689.34 | 676.3 | 1,083 |
EBITDA Margin | 18.42% | 8.68% | 17.52% | 15.96% | 24.98% |
D&A For EBITDA | 368.47 | 265.24 | 251.51 | 91.61 | 78.45 |
EBIT | 563.11 | 66.82 | 437.83 | 584.69 | 1,005 |
EBIT Margin | 11.13% | 1.75% | 11.13% | 13.80% | 23.17% |
Effective Tax Rate | 26.23% | 24.62% | 30.38% | - | 7.92% |
Revenue as Reported | 5,094 | 3,850 | 4,010 | 4,294 | 4,427 |